Biologic Sequencing in Systemic Lupus Erythematosus: After Secondary Non-response to Rituximab, Switching to Humanised Anti-CD20 Agent Is More Effective Than Belimumab. (2020)
Attributed to:
MAximizing Sle ThERapeutic PotentiaL by Application of Novel and Stratified approaches (MASTERPLANS)
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.3389/fmed.2020.00498
PubMed Identifier: 32984378
Publication URI: http://europepmc.org/abstract/MED/32984378
Type: Journal Article/Review
Volume: 7
Parent Publication: Frontiers in medicine
ISSN: 2296-858X